Abstract
Rebound insomnia was studied in subjects, aged 25–50 years, with insomnia complaints and normal sleep, insomnia complaints and disturbed sleep, and normal sleep with no complaints (N=21,n=7 per group). Standard sleep recordings were collected on a baseline night and after abrupt discontinuation of 6 nights of 0.50 mg triazolam, tapered discontinuation (3 nights of 0.50 mg, 2 nights of 0.25 mg, and 1 night of 0.125 mg triazolam) and 6 nights of placebo. Significantly disturbed sleep on the discontinuation night compared to the baseline night was found. The relative degree of rebound insomnia was greater in the abrupt condition than in either the tapered or placebo conditions. The tapered condition reduced sleep time by half that of the abrupt condition which was twice the reduction found in the placebo condition. An overall (regardless of group or condition) difference in baseline versus discontinuation sleep was found, suggesting that pill discontinuation itself leads to sleep disturbance. Subjects did not differ in rebound insomnia as a function of pre-existing sleep disturbance.
Similar content being viewed by others
References
Bixler E, Kales A, Soldatos C, Scharf M, Kales J (1978) Effectiveness of temazepam with short-, intermediate-, and long-term use: sleep laboratory evaluation. J Clin Pharmacol 18:110–118
Clinthrone J, Cisin I, Balter M, Mellinger G, Uhlenhuth E (1986) Changes in popular attitudes and beliefs about tranquilizers. Arch Gen Psychiatry 43:527–532
Greenblatt D, Harmatz J, Zinny M, Shader R (1987) Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. New Engl J Med 12:722–728
Hull J, Bond C (1986) Social and behavioral consequences of alcohol consumption and expectancy: a meta-analysis. Psychol Bull 99:347–360
Kales A, Scharf M, Kales J (1978) Rebound insomnia: a new clinical syndrome. Science 201:1039–1040
Kales A, Bixler E, Soldatos C, Vela-Bueno A, Jacoby J, Kales J (1982) Quazepam and flurazepam: long-term use and extended withdrawal. Clin Pharmacol Ther 32:781–788
Kales A, Soldatos C, Bixler E, Kales J (1983) Rebound insomnia and rebound anxiety: a review. Pharmacology 26:121–137
Merlotti L, Roehrs T, Zorick F, Stepanski E, Russo L, Roth T (1991) Rebound insomnia, duration of administration and individual differences. J Clin Psychopharmacol
Rechtschaffen A, Kales A A manual of standardized terminology techniques and scoring system for sleep stages of human subjects. National Institutes of Health Publ. 204, Government Printing Office, Washington DC
Roehrs T, Zorick F, Wittig R, Roth T (1986) Dose determinants of rebound insomnia. Br J Clin Pharmacol 22:143–147
Roehrs T, Koshorek G, Merlotti L, Zorick F, Wittig R, Roth T (1990a) Dose related effects on rebound insomnia. Sleep Res 19:84
Roehrs T, Vogel G, Roth T (1990b) Rebound insomnia: its determinants and significance. Am J Med 88:39S-42S
Roehrs T, Merlotti L, Zorick F, Roth T (1991) Rebound insomnia and benzodiazepine hypnotic self administration. Psychopharmacology 107: -
Vela-Bueno A, Oliveros J, Dobladez-Blanco B, Arrigain-Ijurra S, Soldatos C, Kales A (1983) Brotizolam: a sleep laboratory evaluation. Eur J Clin Pharmacol 25:53–56
Winokur A, Rickles K (1981) Withdrawal and pseudowithdrawal from diazepam therapy. J Clin Psychiatry 42:442–444
Zorick F, Kribbs N, Roehrs T, Roth T (1984) Polysomnographic and MMPI characteristics of patients with insomnia. In: Hindmarch I, Ott H, Roth T (eds) Sleep, benzodiazepines and performance. Springer, Berlin Heidelberg New York, pp 2–10
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roehrs, T., Merlotti, L., Zorick, F. et al. Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation. Psychopharmacology 108, 67–71 (1992). https://doi.org/10.1007/BF02245287
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245287